Public health and human rights organisations from Kenya, Uganda and Malawi filed a third-party observation with the African Regional Intellectual Property Organization (ARIPO) on August 31, challenging all 43 claims in a Gilead Sciences patent application covering prodrug compounds related to the HIV medicine lenacapavir. ARIPO, a Harare-based intergovernmental intellectual property organisation grants and administers...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.